Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 173Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 154Lymphoma, Large B-Cell, Diffuse 134Lymphoma, Follicular 131Lymphoma, Mantle-Cell 93Leukemia 68Lymphoma, B-Cell, Marginal Zone 67Waldenstrom Macroglobulinemia 49Burkitt Lymphoma 43Lymphoma, B-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Hodgkin Disease 36Recurrence 24Lymphoma, Large-Cell, Immunoblastic 24Neoplasms 15Myelodysplastic Syndromes 15Lymphoma, Large-Cell, Anaplastic 15Multiple Myeloma 13Leukemia, Myeloid, Acute 12Lymphoma, T-Cell, Cutaneous 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoblastic Lymphadenopathy 8Sezary Syndrome 7Mycosis Fungoides 7Lymphoma, T-Cell 7

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Opsoclonus-Myoclonus Syndrome × Rituximab × Clear all
NCT00202930 2021-01-22

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

University of Pittsburgh

Phase 2 Terminated
4 enrolled 6 charts
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡